New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2014
10:02 EDTSPPISpectrum weakness attributed to FDA comment on Fusilev generics
The move lower in shares of Spectrum is being attributed to circulation of a Department of Health and Human Services document which states the FDA will be able to approve abbreviated new drug applications for levoleucovorin calcium, the trade name of Spectrum's Fusilev. Shares of Spectrum are down 4%, or 33c, to $7.42. Reference Link
News For SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SPPI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use